CD274 and neoplasm: In patients with tumor-cell PD-L1 ≥ 1%, NIVO + Chemo numerically increased the median OS versus Chemo (17.3 vs. 9.0 months) and reduced the risk of death by 47% (HR 0.53 [0.35–0.82]); the 12-month OS rate was 64% versus 36%, respectively (Fig. 2a).